Sernova Corp.

Sernova Corp. (TSX VENTURE: SVA) - Sernova Corp. today announced the successful conclusion of a meeting with the U.S.

Sernova Corp. ("Sernova") (TSX VENTURE: SVA) is pleased to announce that world class, pancreatic islet transplant expert, Dr.

Sernova Corp. (TSX VENTURE: SVA) is pleased to announce that the company will be meeting with the United States Food and Drug Administration (FDA) on April 25, 2008 regarding Sertolin, the company's investigational cellular therapy being developed for diabetes treatment.

Sernova Corp. (TSX VENTURE: SVA) ("Sernova") is pleased to announce completion of a comprehensive preclinical efficacy animal study for its lead product Sertolin, which is a combination of porcine Sertoli cells and pancreatic islet cells for the treatment of diabetes.